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Abstract: Serotonin (5-hydroxytryptamine [5-HT]) has been implicated in a variety of physiological and pathological 
functions. Multiple steps of enzyme reactions enable biosynthesis of 5-HT. The ﬁ  rst and rate-limiting step of the reaction 
is the synthesis of 5-hydroxy-L-tryptophan (5-HTP) from L-tryptophan. This step is dictated by an enzyme, tryptophan 
hydroxylase (TPH). TPH requires 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) as a co-substrate of TPH. 5-HTP has 
been simply regarded as a precursor of 5-HT and it is believed that the biological signiﬁ  cance of 5-HTP is essentially 
ascribed to the production of 5-HT. However, recent works shed light on the speciﬁ  c functions of 5-HTP in the periphery. 
In this review article, we focus on the speciﬁ  c roles of exogenous 5-HTP as well as the endogenous 5-HTP in the 
gut epithelial cells. Since systemic treatment with 5-HTP is applied to patients with lower 5-HT levels, the studies on 
the speciﬁ  c role of 5-HTP might create an opportunity to explore the effects of exogenously-applied 5-HTP in the gut 
in man.
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Introduction
Serotonin (5-hydroxytryptamine [5-HT]) has been implicated in a number of physiological and 
pathological functions in the central nervous system as well as several peripheral organs and tissues 
such as the liver, platelets and immune systems.
1–6
In the periphery, a majority of 5-HT is produced and stored in the enterochromafﬁ  n cells in the gut.
7 
Part of 5-HT is also stored in the platelets that release 5-HT in multiple peripheral organs. It has been 
believed that the released 5-HT essentially exerts the biological effects via 5-HT receptors on various 
cells in a paracrine fashion. There are many types of 5-HT receptors that are distributed widely among 
endocrine, cardiovascular, immune, and gastrointestinal tissues. Receptors for 5-HT fall into one of 
four distinct families (5-HTR1, 5-HTR2, 5-HTR3, 5-HTR4-7), which are characterized by different 
signal transduction and physiological roles. Numerous studies have suggested associations between 
various neuropsychiatric disorders and genes that modulate 5-HT neurotransmission such as the 5-HT 
transporter and 5-HT receptors.
8,9 Therefore, transport of 5-HT and signal transduction through 5-HT 
receptors play direct roles in neuronal functions elicited by 5-HT. In fact, selective serotonin reuptake 
inhibitors are used for the treatment of several psychiatric disorders.
9,10
Administration of 5-hydroxy-L-tryptophan (5-HTP), a 5-HT precursor can be used to correct 5-HT 
concentration in the brain of some patients with phenylketonuria.
11 Hyperphenylalaninemia seen in 
phenylketonuria is associated with a decrease in availability of biogenic amines in the brain.
12 Early 
studies reported reduced levels of dopamine, norepinephrine and 5-HT in post mortem brain tissue,
13 
and recent reports indicate reduced aminergic synthesis in the brain of adult phenylketonuria patients 
on phenylalanine-free diet
14 and in mild hyperphenylalaninemia with neurological signs.
15 Although 
5-HTP has been detected biochemically
16 and 5-HTP-immunoreactivity has been visualized in 
neurons,
17–19 it has been generally assumed that 5-HTP is immediately decarboxylated to 5-HT and 
consequently little 5-HTP exists in the CNS.
20
Although the speciﬁ  c functions of 5-HTP in the brain have not been reported, some works shed light 
on speciﬁ  c functions of 5-HTP in the extraneuronal cells.
21,22 This article reviews the mechanisms of 
5-HTP synthesis by focusing on 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4), a co-substrate for 38
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tryptophan hydroxylase (TPH). Then, the speciﬁ  c 
role of 5-HTP in the periphery that is independent 
of 5-HT is discussed.
Production of 5-HTP
In the pathway of 5-HT biosynthesis, TPH, a mem-
ber of a family of pterin-dependent aromatic amino 
acid hydroxylases, catalyzes the formation 
of 5-hydroxy-L-tryptophan (5-HTP) from 
L-tryptophan, which is the ﬁ  rst step in the biosyn-
thesis of the neurotransmitter 5-HT.
23–26 Aromatic 
L-amino-acid decarboxylase (AADC) subsequently 
mediates the production of 5-HT. TPH is a mono-
oxygenase, which incorporates one atom of oxygen 
from molecular oxygen into the substrate and 
reduces the other atom to water. The two electrons 
required for the reduction of the second atom to 
water are supplied by BH4. BH4 acts as the co-
substrate for TPH rather than as a tightly bound 
cofactor.
25,26 Since Km of TPH for BH4 is rather 
large, TPH activity is dependent on cytosolic con-
centration of the co-substrate BH4. The mechanism 
of how the cytosolic level of BH4 is maintained is 
therefore important in the understanding of 5HT 
production in a living cell.
To date, complete deﬁ  ciency of TPH activity 
has not been described in man.
27 But inherited 
disorders affecting BH4 metabolism, in general, 
lead to severe deﬁ  ciency of 5-HT as well as dopa-
mine within the central nervous system. The excep-
tions are dominantly inherited GTP cyclohydrolase 
deﬁ  ciency, where only dopamine metabolism is 
affected, and pterin 4a-carbinolamine dehydratase 
deficiency and milder forms of 6-pyruvoyl-
tetrahydropterin synthase deficiency, where 
neurotransmitter metabolism appears normal.
27 
Thus, the focus was on the kinetics of BH4 that 
highly inﬂ  uences TPH activity and 5-HTP produc-
tion. Factors regulating TPH activity other than 
BH4, such as phosphorylation and ferrous iron, are 
essentially introduced in other articles.
28–32
BH4 is also an essential cofactor for aromatic 
amino acid hydroxylases of phenylalanine
33 
and tyrosine,
34 fatty acid glycerylether oxygen-
ase,
35 and nitric oxide (NO) synthase.
36,37 The 
biosynthetic pathway of BH4 involves at least 4 
essential enzymes, GTP-cyclohydrolase I, 6-pyru-
voyl-tetrahydropterin synthase, 6-pyruvoyl-
tetrahydropterin 2'-reductase and sepiapterin 
reductase.
38–40 The immediate precursor of BH4 in 
the de novo synthetic pathway is believed to be 
6-lactoil-tetrahydropterin, a substrate of sepiapterin 
reductase which catalyzes reduction of a ketone 
to hydroxyl of the C6-side chain of either 
tetrahydro- or dihydro-form of pterin, respectively. 
Sepiapterin is a dihydro form of 6-lactoil-pterin. 
Since biopterin-deﬁ  cient mutants of sepia of a fruit 
ﬂ  y Drosophila melanogaster and lemon of a silk 
worm Bombyx mori deposited Sepiapterin, this 
pterin was long believed to be the intermediate in 
biopterin biosynthesis.
41
BH4 supplementation has been used in BH4-
deﬁ  cient patients for a long time.
42 BH4 supple-
mentation is used in BH4-deﬁ  cient patients to 
decrease phenylalanine levels in patients in whom 
hyperphenylalaninemia is present,
42 because BH4 
deﬁ  ciency also leads to dysfunction of phenyl-
alanine hydroxylase activity. BH4 is used for the 
treatment of or as alternative therapy for or in 
experimental trials of inborn errors in enzymes in 
BH4 biosynthesis or BH4 recycling such 
as BH4-responsive phenylketonuria, GTP-
cyclohydrolase I deficiency, mild and severe 
forms of 6-pyruvoyl-tetrahydropterin sysnthase 
deﬁ  ciency and pterin-4a-carbinolamine dehydra-
tase deﬁ  ciency.
11 Since BH4 is an essential cofac-
tor in the production of the neurotransmitters, 
5-HT and dopamine, and also in the generation 
of NO by NO-synthase, a vast range of vascular 
and neural disease states have been recognized to 
potentially beneﬁ  t from effective BH4 supple-
mentation.
43 However, BH4 does not easily cross 
the blood brain barrier and cannot be used to cor-
rect the central neurotransmitter deﬁ  ciency in any 
of the BH4 deﬁ  ciencies.
42 In these patients cor-
rection of neurotransmitter deﬁ  ciency is achieved 
by administering L-dopa and 5-HTP,
42 which 
bypass the metabolic block and are converted to 
dopamine and 5-HT, respectively. These precur-
sors are normally given together with peripheral 
AADC inhibitor that prevents peripheral decar-
boxylation of the precursors and allows the pre-
cursors to enter the brain.
27 5-HTP is used for the 
treatment of or as alternative therapy for or in 
experimental trials of disorders such as dihydrop-
teridine reductase deficiency and sepiapterin 
reductase deﬁ  ciency.
11
The consequence of BH4 supplementation 
provided a hypothesis that administered BH4 
might have extremely low efﬁ  ciency of uptake 
and/or short retention period. BH4 might not 
enter cells merely by passive diffusion owing to 
its hydrophilic nature. Indeed, BH4 is much less 39
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permeable across the cell membrane than 
sepiapterin or dihydrobiopterin, the precursors of 
the BH4-salvage pathway. It is likely that special 
mechanisms maintain a steady endogenous level 
of BH4 in the cells, and exploration of such 
mechanisms serves for efﬁ  cient biosynthesis of 
5-HTP. Therefore, some mechanisms for BH4 
transport were studied.
Using RBL2H3 cells, a 5-HT-producing mast cell 
line, BH4 which was transiently taken up appeared 
to be oxidized to dihydrobiopterin (BH2) and then 
released. Cells virtually do not take up BH4 in its 
reduced form, but they do take up BH2 produced 
from the administered BH4 and convert it back to 
BH4 through the salvage pathway; a process which 
was shown to result in an apparent accumulation of 
BH4. Consequently, BH4 accumulation in RBL2H3 
cells was characterised by its sensitivity to metho-
trexate, an inhibitor of dihydrofolate reductase.
44,45 
This machinery was also the case in the hepatocytes 
because accumulation of BH4 in hepatocytes was 
almost completely inhibited by methotrexate.
46 The 
outline of this feature of BH4 accumulation is 
depicted in Figure 1.
This model was also supported in vivo.
47,48 
When mice were treated with 6R-BH4, BH2 or 
sepiapterin either via the oral or intraperitoneal 
route, it was found that sepiapterin was able to 
increase tissue BH4 levels most efficiently; a 
smaller increase in tissue biopterin levels after oral 
administration of equivalent doses of 6R-BH4 and 
BH2 was also observed. The dihydrobiopterin 
surge seen after BH4 treatment suggested that 
systemic oxidation of the administered BH4 
occurred before accumulation of BH4 in the 
tissues. This idea was supported by the following 
observations: 1) Increase in tissue BH4 was 
effectively inhibited by methotrexate. 2) When the 
methotrexate
stable
BH2
BH2
BH2
BH2
BH4
BH4 BH4
Intestinal epithelial cell Mast cell
Hepatocyte
BH4
BH4
oxidation
transient
Figure 1. Cell-type speciﬁ  c biopterin transport into the cell. Intestinal epithelial cells (Caco-2) takes up BH4 in its reduced form and releases 
it from the other side of the polar cell body. In contrast, 5-HT-producing mast cell (RBL2H3 cells) and phenylalanine-metabolizing hepatocyte 
(primary culture) rapidly take up BH4. Then, BH4 is immediately oxidized to BH2 and is exported back to the extracellular space. Finally, 
BH2 in the extracellular space enters the cells and contributes to the production of BH4.40
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unnatural diastereomer 6SBH4 was administered 
to mice, a large proportion of the recovered BH4 
was in the form of the 6R-diastereomer, suggesting 
that this BH4 was the product of a dihydrofolate 
reductase process by which 7,8-dihydrobiopterin, 
a non-chiral BH2, converts to 6RBH4. The exog-
enous BH4 is oxidized and the resultant BH2 
circulates through the tissues, and then it was 
incorporated by various other tissues and organs 
through a pathway shared by the exogenous 
sepiapterin and BH2 in their uptake. Thus, main-
taining endogenous BH4 in tissues under ordinary 
conditions is largely dependent on a methotrexate-
sensitive process. Together, in addition to intracel-
lular BH4 produced by de novo synthesis, BH4 can 
be also generated from sepiapretin in the extracel-
lular space by salvage pathway and from BH2 
taken up from the extracellular space (Fig. 1). 
BH2,which is present in the extracellular space 
enters the cells. Exogenous sepiapterin, if available, 
is also able to enter the cells. Both sepiapterin and 
BH2 taken up from the extracellular space contrib-
ute to the production of BH4 in the cells.
44,45
On the other hand, recent studies on intestinal 
absorption of BH4 demonstrated that in mice, 
orally administered BH4 was absorbed in the small 
intestine as efﬁ  ciently as BH4 injected in the peri-
toneal cavity.
47,49 To support this ﬁ  nding, rapid 
trans-cellular transport of BH4 was observed across 
monolayer culture of Caco-2 cells of intestinal 
epithelial origin on ﬁ  lter membrane.
50 Furthermore, 
6SBH4, a synthetic diastereomer of BH4, was 
loaded into Caco-2 cells and the accumulated BH4 
was identiﬁ  ed as 6SBH4.
46 These results provided 
strong evidence that BH4 had directly accumulated 
in Caco-2 cells. The BH4 in the cells is immediately 
released from the cells, and hence the process is 
insensitive to methotrexate. Thus, the mechanism 
of BH4 transport across plasma membrane of Caco-
2 cells is distinctive from that of RBL2H3 cells. 
The discovery of distinct mechanisms of BH4 
transport among various cells in peripheral organs 
might have a potential to open up new approaches 
that regulate the amount of 5-HTP in the gut.
Speciﬁ  c Role of 5-HTP
It has been generally assumed that 5-HTP, a 5-HT 
precursor, is immediately decarboxylated to 5-HT 
and consequently little 5-HTP exists.
20 However, a 
report presented an interesting ﬁ  nding on 5-HTP in 
an immune cell. 5-HT protected NK cells from 
monocyte-mediated apoptosis and suppression of 
cytotoxicity and maintained the activation of NK 
cells induced by interleukin-2, and these protective 
effects revealed that 5-HT scavenged reactive 
oxygen species derived from the myeloperoxidase 
system. Interestingly, 5-HTP shared the scavenger 
activity with 5-HT; however, the potency of 5-HT 
was greater by more than 10-fold when compared 
to 5-HTP in protecting NK cells against functional 
inhibition and apoptosis.
21 This observation raises 
a possibility that exogenous 5-HTP itself as well as 
the endogenous 5-HTP might function in the extra-
neuronal cells. This hypothesis was tested using the 
macrophages. Evidence suggests that 5-HT modu-
lates immune functions through several 5-HT 
receptors including 5-HT1A receptor.
51 For instance, 
the application of 5-HT induced an increase in 
macrophage phagocytosis that is blocked by the 
5-HT1A receptor antagonist WAY100635,
52 indicat-
ing that exogenous 5-HT contributes to phagocy-
tosis and the enhancing effect is partly mediated by 
the 5-HT1A receptor. Peritoneal macrophages col-
lected from mice after stimulation with thioglycol-
late, an activator of macrophages, were found to 
express TPH protein.
22 Consistently, these cells had 
5-HTP endogenously. Nevertheless, either exoge-
nous or endogenous 5-HTP did not enhance the 
phagocytic activity in vitro.
22
Although the role of 5-HTP in the phagocytic 
activity of macrophages was not found, a 5-HT-
independent role of 5-HTP was further investigated 
in the intestinal epithelial cells.
22 5-HT has several 
physiological and pathological implications in the 
gut as well as in the brain. For example, 5-HT has 
been reported to increase the rate at which entero-
cyte precursors proliferate, and the enhancement 
of enterocyte proliferation by 5-HT might be medi-
ated by a 5-HT2 receptor.
53 Patients with celiac 
disease have increased 5-HT-containing entero-
chromafﬁ  n cell numbers and signiﬁ  cantly higher 
peak plasma 5-HT and platelet 5-HT stores than 
controls, which correlate with postprandial dys-
pepsia.
54 On the other hand, the biological activities 
of 5-HTP itself have not been essentially explored 
in the gut. Enormous amounts of 5-HT are pro-
duced in the enterochromafﬁ  n cells and mast cells.
7 
The expression of TPH was, therefore, expected 
to be conﬁ  ned to enterochromafﬁ  n cells and mast 
cells in the intestine. Unexpectedly, TPH-1 was 
also found in the epithelial cells of mucosa in the 
rodent intestine.
22 Similar results were obtained in 
the human duodenum using anti-TPH antibody.
55 41
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The distribution of TPH-1 inside the cells was not 
uniform.
22 TPH-1 was abundant on the apical side 
of the villi epithelium as well as in other cytoplas-
mic regions.
22 Moreover, TPH-1 was found in the 
brush border in the gut epithelial cells by immu-
nohistochemistry with the isolated brush border 
fraction.
22 The distribution of endogenous 5-HTP 
overlapped with that of TPH-1 on the apical side 
of the villi epithelium.
22 Although immunoreactivity 
for 5-HT was not obtained in the intestinal 
epithelial cells expressing TPH-1 except for 
enterochromafﬁ  n cells, HPLC analysis showed that 
Caco-2 of intestinal epithelial origin synthesized 
small but deﬁ  nite amount of 5-HT de novo.
22
Intriguingly, the functions of endogenous 
5-HTP as well as exogenously-applied 5-HTP was 
shown using inhibitors of 5-HT synthesis cascade 
(Fig. 2A). Analyses with electron microscopy 
revealed that systemic application of 5-HTP 
increased the density of microvilli in the mouse 
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Figure 2. 5-HTP regulates the formation of microvilli in the intestine. A) Schematic representation of the actions of serotonergic inhibitors. 
B) Transmission electron microscopic analysis of the microvilli of intestine in mice treated with 5-HTP. Scale bar, 100 nm. C) Scanning 
electron microscopic analysis of Caco-2 cells treated with 5-HTP, 5-HT, PCPA, 5-HTP plus PCPA, NSD-1015, NSD-1015 plus 5-HTP, and 
NSD-1015 plus PCPA. The density of microvilli was quantitatively estimated. Reprinted from Am J Pathol. 2008;172:333–344 with permission 
from the American Society for Investigative Pathology.42
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intestine in vivo (Fig. 2B). That was also the case 
in the microvilli of Caco-2 cells (Fig. 2C). Exog-
enous 5-HTP, which can enter the cells, increased 
the density of microvilli; however, exogenous 
5-HT did not. In addition, when exogenous 5-HTP 
was applied together with p-chlorophenylalanine 
(PCPA), a TPH inhibitor, the density was also 
increased, indicating that exogenous 5-HTP plays 
a role without the effect of endogenous 5-HTP. To 
conﬁ  rm the speciﬁ  c role of exogenous 5-HTP in 
the development of microvilli without the effect 
of 5-HT, 3-hydroxybenzylhydrazine (NSD-1015), 
an AADC inhibitor, was used (Fig. 2A). NSD-1015 
blocks the synthesis of 5-HT and induces the accu-
mulation of 5-HTP (Fig. 1A). When 5-HTP was 
given together with NSD-1015, the density was 
higher than when NSD-1015 was given alone. 
Thus, the effect is dependent on exogenous 5-HTP. 
The roles of endogenous 5-HTP were then 
assessed. Application of PCPA resulted in a 
decrease in the density of microvilli. To distinguish 
5-HTP from 5-HT, NSD-1015 was used. An 
increase in the density was observed after the 
application of NSD-1015. Furthermore, the addi-
tion of PCPA together with NSD-1015 resulted in 
a lower density than the addition of NSD-1015 
alone. These results suggest that endogenous 
5-HTP also plays a role in the density of microvilli. 
It is still unknown whether the small amount of 
5-HT produced in the gut epithelial cells might 
contribute to the functions of the gut such as 
gastrointestinal motility and absorption via 5-HT 
receptors.
Conclusion
Physiological roles of 5-HTP in the brain have not 
been reported. On the other hand, 5-HTP has a 
speciﬁ  c function in the gut. As a unique BH4 
transport mechanism, BH4 that transiently enters 
cells can be rapidly oxidized to BH2 and is 
exported back to the extracellular space. Mean-
while, the intestinal epithelial cells take up BH4 
as its reduced form. Therefore, the intestine shares 
a unique BH4 transporter mechanism and a spe-
ciﬁ  c function of 5-HTP. Further studies would 
clarify the intestine-speciﬁ  c machinery linking the 
speciﬁ  c mechanism of BH4-dependent 5-HTP 
production to the speciﬁ  c function of 5-HTP. 
A 5-HT precursor 5-HTP is sometimes adminis-
tered to patients with metabolic disorder.
27 The 
ﬁ  nding on the function of 5-HTP in the intestine 
might create an opportunity to explore the effects of 
exogenously-applied 5-HTP on the intestine in man.
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